Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

USFDA has cleared the world’s first oral therapy for the condition, a development that health experts say could transform ...

PKM2 acts like a switch for cellular energy, directly determining whether cancer cells can rapidly generate energy and biosynthetic precursors to support their continued growth. Using a driving ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, ...

Agios Pharma's shares soar 16% after FDA expands approval for its blood disorder drug, Aqvesme, set for late next month.

BHUBANESWAR: The New Year seems to have ushered in a major breakthrough for thalassaemia patients with the US Food and Drug ...

The US Food and Drug Administrations (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks ...

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. This approval marks a significant breakthrough offering hope to patients reliant on lifelong blood ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...